ProMIS Neurosciences Secures $175M Financing to Advance Alzheimer’s Trial
Event summary
- ProMIS Neurosciences closed a PIPE financing round with gross proceeds of up to $175 million, including potential warrant exercises.
- The company’s Phase 1b PRECISE-AD trial for Alzheimer’s disease is fully enrolled and progressing on schedule, with a blinded 6-month interim analysis expected in early Q3 2026.
- PMN310, the lead drug candidate, is designed to selectively target toxic amyloid-beta oligomers, potentially reducing ARIA-related risks associated with current therapies.
- ProMIS expects to complete 12-month dosing for all patients by year-end 2026 and report unblinded top-line results in early 2027.
The big picture
ProMIS Neurosciences’ $175 million financing round positions the company to advance its Phase 1b trial for Alzheimer’s disease, addressing a critical unmet need in neurodegenerative therapies. The selective targeting approach of PMN310 aims to mitigate the safety concerns associated with current treatments, potentially offering a more effective and safer option for patients. The upcoming interim data readout will be a key indicator of the drug’s potential, with broader implications for the Alzheimer’s treatment landscape.
What we're watching
- Clinical Efficacy
- How the blinded interim analysis in early Q3 2026 will reveal early insights into PMN310’s target engagement and safety profile.
- Market Differentiation
- Whether PMN310’s selective targeting of toxic oligomers can offer a differentiated safety and efficacy profile compared to existing Alzheimer’s therapies.
- Financial Runway
- The pace at which ProMIS will deploy its $175 million in financing to support its clinical and pipeline development through 2027.
Related topics